We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genincode Plc | LSE:GENI | London | Ordinary Share | GB00BL97B504 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 8.25 | 8.00 | 8.50 | 8.25 | 8.25 | 8.25 | 19,053 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 1.43M | -5.56M | -0.0580 | -1.42 | 7.9M |
From May 2023 to May 2024
By Ian Walker
Shares of GENinCode rose 17% after the company said that it has filed a premarket notification with the U.S. Food and Drug Administration for its coronary heart disease risk assessment test kit, Cardio inCode-Score.
Shares at 1106 GMT were up 2.0 pence at 13.50 pence.
The London-listed predictive genetics company said Wednesday that approval will enable the expansion and commercial distribution of the device in the U.S.
It expects to receive FDA approval for the device over the next six months.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
August 16, 2023 07:26 ET (11:26 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Genincode Chart |
1 Month Genincode Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
